Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

Flavio Airoldi, Antonio Colombo, Nuccia Morici, Azeem Latib, John Cosgrave, Lutz Buellesfeld, Erminio Bonizzoni, Mauro Carlino, Ulrich Gerckens, Cosmo Godino, Gloria Melzi, Iassen Michev, Matteo Montorfano, Giuseppe Massimo Sangiorgi, Asif Qasim, Alaide Chieffo, Carlo Briguori, Eberhard Grube

Research output: Contribution to journalArticlepeer-review

431 Scopus citations


BACKGROUND - The need for prolonged aspirin and thienopyridine therapy and the risk of stent thrombosis (ST) remain as drawbacks associated with drug-eluting stents. METHODS AND RESULTS - A prospective observational cohort study was conducted between June 2002 and January 2004 on 3021 patients consecutively and successfully treated in 5389 lesions with drug-eluting stents. Detailed patient information was collected on antiplatelet therapy. We analyzed the incidence of ST throughout the 18-month follow-up period and its relationship with thienopyridine therapy. ST occurred in 58 patients (1.9%) at 18 months. Forty-two patients (1.4%) experienced the event within 6 months of stent implantation. Acute myocardial infarction (fatal or nonfatal) occurred in 46 patients (79%) and death in 23 patients (39%) with ST. The median interval from discontinuation of thienopyridine therapy to ST was 13.5 days (interquartile range 5.2 to 25.7 days) for the first 6 months and 90 days (interquartile range 30 to 365 days) between 6 and 18 months. On multivariable analysis, the strongest predictor for ST within 6 months of stenting was discontinuation of thienopyridine therapy (hazard ratio, 13.74; 95% CI, 4.04 to 46.68; P<0.001). Thienopyridine discontinuation after 6 months did not predict the occurrence of ST (hazard ratio, 0.94; 95% CI, 0.30 to 2.98; P=0.92). CONCLUSIONS - Discontinuation of thienopyridine therapy was the major determinant of ST within the first 6 months, but insufficient information is available to determine whether there is benefit in continuing a thienopyridine beyond 6 months.

Original languageEnglish (US)
Pages (from-to)745-754
Number of pages10
Issue number7
StatePublished - Aug 2007
Externally publishedYes


  • Coronary disease
  • Stents
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment'. Together they form a unique fingerprint.

Cite this